183 related articles for article (PubMed ID: 15596192)
1. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999.
Zeliadt SB; Potosky AL; Etzioni R; Ramsey SD; Penson DF
Urology; 2004 Dec; 64(6):1171-6. PubMed ID: 15596192
[TBL] [Abstract][Full Text] [Related]
2. Racial, Socioeconomic, and Geographic Disparities in the Receipt, Timing to Initiation, and Duration of Adjuvant Androgen Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
J Racial Ethn Health Disparities; 2019 Feb; 6(1):133-142. PubMed ID: 29959759
[TBL] [Abstract][Full Text] [Related]
3. Racial treatment trends in localized/regional prostate carcinoma: 1992-1999.
Underwood W; Jackson J; Wei JT; Dunn R; Baker E; Demonner S; Wood DP
Cancer; 2005 Feb; 103(3):538-45. PubMed ID: 15612083
[TBL] [Abstract][Full Text] [Related]
4. Treatment for older prostate cancer patients: disparities in a southern state.
Pisu M; Oliver JS; Kim YI; Elder K; Martin M; Richardson LC
Med Care; 2010 Oct; 48(10):915-22. PubMed ID: 20733530
[TBL] [Abstract][Full Text] [Related]
5. Trends and black/white differences in treatment for nonmetastatic prostate cancer.
Klabunde CN; Potosky AL; Harlan LC; Kramer BS
Med Care; 1998 Sep; 36(9):1337-48. PubMed ID: 9749657
[TBL] [Abstract][Full Text] [Related]
6. Trends and racial differences in the use of androgen deprivation therapy for metastatic prostate cancer.
Carson AP; Howard DL; Carpenter WR; Taylor YJ; Peacock S; Schenck AP; Godley PA
J Pain Symptom Manage; 2010 May; 39(5):872-81. PubMed ID: 20471547
[TBL] [Abstract][Full Text] [Related]
7. Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer.
Godley PA; Schenck AP; Amamoo MA; Schoenbach VJ; Peacock S; Manning M; Symons M; Talcott JA
J Natl Cancer Inst; 2003 Nov; 95(22):1702-10. PubMed ID: 14625261
[TBL] [Abstract][Full Text] [Related]
8. Race and Time to Receipt of Androgen Deprivation Therapy Among Men With Metastatic Prostate Cancer.
Cobran EK; Young HN; Chen RC; Chen X; Reeves J; Godley PA; Shah S
J Natl Med Assoc; 2019 Jun; 111(3):246-255. PubMed ID: 30389146
[TBL] [Abstract][Full Text] [Related]
9. Hospital racial composition and the treatment of localized prostate cancer.
Pollack CE; Bekelman JE; Liao KJ; Armstrong K
Cancer; 2011 Dec; 117(24):5569-78. PubMed ID: 21692067
[TBL] [Abstract][Full Text] [Related]
10. Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort.
Du XL; Fang S; Coker AL; Sanderson M; Aragaki C; Cormier JN; Xing Y; Gor BJ; Chan W
Cancer; 2006 Mar; 106(6):1276-85. PubMed ID: 16475208
[TBL] [Abstract][Full Text] [Related]
11. Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer.
Wang C; Raldow AC; Nickols NG; Nguyen PL; Spratt DE; Dess RT; Yu JB; King CR; Chu FI; Chamie K; Litwin MS; Saigal CS; Reiter RE; Liu ST; Rettig MB; Chang AJ; Steinberg ML; Kupelian PA; Kishan AU
Eur Urol Oncol; 2021 Apr; 4(2):327-330. PubMed ID: 31411981
[TBL] [Abstract][Full Text] [Related]
12. Predictors of aggressive therapy for nonmetastatic prostate carcinoma in Massachusetts from 1998 to 2002.
Rose AJ; Backus BM; Gershman ST; Santos P; Ash AS; Battaglia TA
Med Care; 2007 May; 45(5):440-7. PubMed ID: 17446830
[TBL] [Abstract][Full Text] [Related]
13. Impact of androgen deprivation therapy on racial/ethnic disparities in the survival of older men treated for locoregional prostate cancer.
Holmes L; Chan W; Jiang Z; Ward D; Essien EJ; Du XL
Cancer Control; 2009 Apr; 16(2):176-85. PubMed ID: 19337204
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
Saigal CS; Gore JL; Krupski TL; Hanley J; Schonlau M; Litwin MS;
Cancer; 2007 Oct; 110(7):1493-500. PubMed ID: 17657815
[TBL] [Abstract][Full Text] [Related]
15. Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy.
Morgans AK; Smith MR; O'Malley AJ; Keating NL
Cancer; 2013 Feb; 119(4):863-70. PubMed ID: 23065626
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the Rate of Adherence to International Guidelines for Androgen Deprivation Therapy with External-beam Radiation Therapy: A Population-based Study.
Dell'Oglio P; Abou-Haidar H; Leyh-Bannurah SR; Tian Z; Larcher A; Gandaglia G; Fossati N; Shariat SF; Capitanio U; Briganti A; Montorsi F; Graefen M; Saad F; Karakiewicz PI
Eur Urol; 2016 Sep; 70(3):429-35. PubMed ID: 26951945
[TBL] [Abstract][Full Text] [Related]
17. Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer.
Schmid M; Meyer CP; Reznor G; Choueiri TK; Hanske J; Sammon JD; Abdollah F; Chun FK; Kibel AS; Tucker-Seeley RD; Kantoff PW; Lipsitz SR; Menon M; Nguyen PL; Trinh QD
JAMA Oncol; 2016 Jan; 2(1):85-93. PubMed ID: 26502115
[TBL] [Abstract][Full Text] [Related]
18. Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer.
Shavers VL; Brown M; Klabunde CN; Potosky AL; Davis W; Moul J; Fahey A
Med Care; 2004 Mar; 42(3):239-50. PubMed ID: 15076823
[TBL] [Abstract][Full Text] [Related]
19. Explaining black-white differences in receipt of recommended colon cancer treatment.
Baldwin LM; Dobie SA; Billingsley K; Cai Y; Wright GE; Dominitz JA; Barlow W; Warren JL; Taplin SH
J Natl Cancer Inst; 2005 Aug; 97(16):1211-20. PubMed ID: 16106026
[TBL] [Abstract][Full Text] [Related]
20. Disparities in treatment patterns and mortality in prostate cancer: Interaction between Black race and end-stage kidney disease.
Sarabu N; Dong W; Koroukian SM
Cancer Med; 2024 May; 13(10):e7027. PubMed ID: 38770622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
